Inhibikase Therapeutics Inc (IKT) - News Archive

Navigating Challenges and Opportunities: Inhibikase Therapeutics Leadership Expansion Amid Financial DynamicsInhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company focused on innovative sma...

Inhibikase Therapeutics Expands Leadership Team Amid Significant Financial MilestonesIn an important strategic move, Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced the expansion of its senior leadership team, app...

In a significant move for the biopharmaceutical sector, Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage company focused on developing innovative therapies targeting cardiopulmonary and neurodegenerative di...

Inhibikase Therapeutics, a renowned clinical-stage pharmaceutical company, has made significant progress in two of its key therapies - risvodetinib and IkT-001Pro. The company recently completed enrollment for the Phase...

Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development ProgramsInhibikase Therapeutics Inc, a leading biopharmaceutical company, has recently made an exciting an...

Inhibikase Therapeutics Update: Advancements in Parkinson s Disease Treatment and Share Price GrowthIn a recent press release, Inhibikase Therapeutics, a clinical-stage pharmaceutical company, issued a Letter to Shareho...

In recent developments, Inhibikase Therapeutics, a clinical-stage pharmaceutical company, has made strides in the field of disease-modifying treatments for Pulmonary Arterial Hypertension (PAH) and Parkinson s disease....

Inhibikase Therapeutics, a renowned clinical-stage pharmaceutical company, is actively involved in the development of protein kinase inhibitor therapeutics to modify the course of Parkinson s disease, Parkinson s-relate...

Inhibikase Therapeutics Sets Ambitious Goals for IkT-001Pro after Successful Pre-NDA Meeting with the FDAIn a recent announcement, leading biopharmaceutical company Inhibikase Therapeutics revealed the successful outcom...

Inhibikase Therapeutics, a leading biopharmaceutical company, recently announced the preliminary outcomes of its pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) regarding the path...

Inhibikase Therapeutics, a groundbreaking clinical-stage pharmaceutical company, is making significant strides in the field of Parkinson s disease and related disorders. Their recent publication in the esteemed Journal...

Inhibikase Therapeutics, a renowned clinical-stage pharmaceutical company, recently issued a Letter to Shareholders outlining updates on its development programs and progress in combating Parkinson s disease (PD) and re...